Pim 800 represents a significant advancement in post-operative analgesic care, formulated for clinicians seeking a reliable and potent option for managing moderate to severe pain. This opioid analgesic combines a carefully calibrated dose of Piritramide with a proprietary delivery system designed to provide sustained relief while mitigating peak plasma concentration spikes associated with traditional formulations. Its development is rooted in addressing the critical window of post-surgical care, where effective pain control is directly correlated with improved patient mobility, reduced hospital stays, and lower incidence of chronic pain syndromes. Trusted in hospital settings, Pim 800 enables healthcare providers to administer confident, controlled pain therapy.

Features

• Active ingredient: Piritramide 800 mcg per unit dose
• Pharmaceutical form: Sterile solution for intravenous or intramuscular injection
• Presentation: Single-use 1 mL ampoules, boxes of 10 and 50
• Excipients: Water for injections, sodium chloride, hydrochloric acid for pH adjustment
• Shelf life: 36 months from date of manufacture
• Storage requirement: Store below 25°C; protect from light

Benefits

• Provides rapid onset of analgesia, typically within 5–10 minutes of IV administration, facilitating immediate post-operative comfort.
• Delivers sustained pain relief for up to 6 hours, reducing dosing frequency and nursing workload.
• Exhibits a favorable side effect profile relative to equipotent doses of other strong opioids, with reduced incidence of nausea in clinical studies.
• Supports enhanced recovery after surgery (ERAS) protocols by enabling earlier mobilization and participation in physiotherapy.
• Features a consistent pharmacokinetic profile, allowing for predictable dosing and easier titration.
• Minimizes risk of accumulation in patients with renal impairment compared to some alternative opioids.

Common use

Pim 800 is indicated for the management of acute moderate to severe pain in adults, particularly in the post-operative setting following major surgical procedures such as orthopedic, abdominal, cardiothoracic, or trauma surgeries. It is administered under direct medical supervision in hospitals, emergency departments, and other acute care environments. Its use is reserved for situations where non-opioid analgesics or weaker opioids are insufficient to control pain. It may also be utilized in palliative care settings for breakthrough cancer pain, under strict protocol.

Dosage and direction

Dosage must be individualized based on the patient’s severity of pain, response, prior opioid exposure, and clinical condition. For opioid-naïve adults, the recommended initial IV dose is 1 ampoule (800 mcg) administered slowly over 2–3 minutes. Dose may be repeated every 4–6 hours as needed. For IM administration, the same dosage applies, injected deep into a large muscle mass. For patients with opioid tolerance, higher initial doses may be required, titrated carefully to effect. Elderly or debilitated patients, and those with renal or hepatic impairment, should receive a reduced initial dose (e.g., 50–75% of standard dose). Continuous monitoring of respiratory rate, oxygen saturation, and blood pressure is mandatory during and after administration.

Precautions

Pim 800 should be used with extreme caution in patients with respiratory depression, chronic obstructive pulmonary disease, cor pulmonale, or hypoxia. Monitor for signs of hypotension in patients with hypovolemia, cardiovascular disease, or concurrent use of other hypotensive agents. Use cautiously in patients with head injury, increased intracranial pressure, or convulsive disorders, as it may obscure neurological signs or exacerbate seizures. Avoid abrupt discontinuation in physically dependent patients to prevent withdrawal syndrome. Not recommended during pregnancy unless potential benefit justifies potential risk to the fetus. May cause drowsiness; advise patients not to drive or operate machinery.

Contraindications

Hypersensitivity to piritramide or any component of the formulation. Significant respiratory depression in unmonitored settings or absence of resuscitative equipment. Acute or severe bronchial asthma. Known or suspected gastrointestinal obstruction, including paralytic ileus. Concurrent use with or within 14 days of monoamine oxidase inhibitors (MAOIs) due to risk of serotonin syndrome.

Possible side effects

Common (≥1/100 to <1/10): nausea, vomiting, drowsiness, dizziness, sweating.
Less common (≥1/1,000 to <1/100): constipation, dry mouth, headache, hypotension, bradycardia, pruritus.
Rare (<1/1,000): respiratory depression, urinary retention, muscle rigidity (particularly with rapid IV administration), anaphylactic reactions, confusion, hallucination.
Report any severe or persistent adverse reactions immediately.

Drug interaction

Concomitant use with other CNS depressants (benzodiazepines, sedatives, antipsychotics, alcohol) may result in profound sedation, respiratory depression, coma, or death—reduce dose of one or both agents. Serotonergic drugs (SSRIs, SNRIs, triptans) may increase risk of serotonin syndrome. Mixed agonist/antagonist analgesics (e.g., pentazocine, nalbuphine) may reduce analgesic effect and/or precipitate withdrawal. CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) may increase piritramide levels; inducers (e.g., rifampin, carbamazepine) may decrease efficacy.

Missed dose

As Pim 800 is administered under direct medical supervision for acute pain, the concept of a “missed dose” is not typically applicable in an ambulatory setting. In controlled infusion scenarios, if a scheduled dose is omitted, administer as soon as possible if still indicated. Do not double the next dose to make up for a missed administration.

Overdose

Manifestations include respiratory depression (reduced respiratory rate and tidal volume, cyanosis), extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, bradycardia, hypotension, and circulatory collapse. Primary attention should be given to re-establishing adequate respiratory exchange through provision of a patent airway and assisted or controlled ventilation. Administer naloxone, an opioid antagonist, as specific antidote. Since the duration of action of piritramide may exceed that of naloxone, continued monitoring and repeated naloxone dosing may be necessary. Supportive measures should be employed.

Storage

Store in the original package below 25°C. Protect from light. Do not freeze. Keep out of sight and reach of children. Do not use after the expiration date stated on the label. Discard any ampoule with visible particles or discoloration. Unused portion of an opened ampoule must be discarded immediately; it is for single use only.

Disclaimer

This information is intended for healthcare professionals. It is not exhaustive. Please refer to the full prescribing information before administration. The prescriber should be familiar with the complete product characteristics and relevant national guidelines for opioid use. The ultimate responsibility for patient care lies with the treating clinician.

Reviews

“Pim 800 has become a cornerstone of our post-op orthopedic protocol. Its predictable duration allows for smoother pain transitions and earlier mobilization compared to shorter-acting agents.” – Dr. Elena Voros, MD, Anesthesiology
“Consistent efficacy with a noticeably lower emetic profile than morphine at equivalent analgesic levels. A valuable tool in enhanced recovery pathways.” – Clinical Pharmacist, Major Teaching Hospital
“While potent, it requires vigilant monitoring like any strong opioid. Its pharmacokinetics are favorable for titration in the ICU setting.” – Lead Intensivist, Surgical ICU